Can a common bone drug help HIV patients fight osteoporosis?
NCT ID NCT00120757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV. 140 participants received either alendronate or a placebo, along with calcium and vitamin D, for 2 years. The goal was to see if the drug could strengthen bones and reduce fracture risk in this population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker service des Maladies Infectieuses
Paris, 75015, France
-
Service de Medecine Interne hopital Avicenne
Bobigny, 93009 cedex, France
-
Service de Rhumatologie hopital Pitie-Salpetriere
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?